• Canagliflozin Remodels Mitochondria in Diabetic Hypertensive

  2026-08-06

  This study reveals that canagliflozin, a selective SGLT2 inhibitor, improves both the structure and function of mitochondria in proximal tubular cells of hypertensive–diabetic mice. These mitochondrial changes may underpin the renal protective effects of SGLT2 inhibition, offering new mechanistic insight for diabetes and kidney disease research.

• Amyloid β-Peptide (1-42): Mechanistic Leverage for Translati

  2026-08-05

  Explore how Amyloid β-Peptide (1-42) (Aβ42) is redefining Alzheimer’s disease (AD) research through mechanistic insight, assay innovation, and translational strategy. This article integrates foundational biology, state-of-the-art ratiometric imaging, and practical protocol guidance, uniquely bridging laboratory rigor with clinical ambition. Building on recent advances and APExBIO’s validated reagent, we chart a course for researchers seeking both robust neurotoxicity models and actionable data for therapeutic development.

• Sex-Biased Gene Expression in Neural Differentiation of hESC

  2026-08-05

  This study provides the first genome-wide analysis of sex-biased gene expression during neural differentiation in multiple human embryonic stem cell lines, independent of hormonal effects. The findings reveal intrinsic genetic sex differences that influence neuronal development trajectories, with implications for understanding sex-specific neurodevelopmental disorders.

• Eliminating Pollen Interference in EEM-Based Hazardous Subst

  2026-08-04

  Zhang et al. (2024) present a robust approach to mitigate pollen-induced spectral interference when classifying hazardous substances via excitation–emission matrix (EEM) fluorescence spectroscopy. By integrating advanced spectral preprocessing, machine learning, and feature transformation, their method significantly improves detection accuracy for bioaerosols—enabling more reliable environmental monitoring and public health protection.

• EV-Transferred ACLY Promotes Immunosuppressive TAMs in HCC

  2026-08-04

  This study reveals that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles (EVs) loaded with ATP-citrate lyase (ACLY), which are taken up by monocytes to drive their differentiation into tumor-associated macrophages (TAMs) with immunosuppressive properties. The findings establish a mechanistic metabolic link between tumor cell-derived EVs, monocyte programming, and immune evasion in liver cancer, suggesting new therapeutic strategies targeting TAMs.

• HEY2 Regulation of Cardiac Mitochondrial Metabolism and Home

  2026-08-03

  This study uncovers HEY2 as a critical transcriptional repressor that modulates mitochondrial oxidative metabolism in the heart. By elucidating the HEY2/HDAC1–PPARGC1/ESRRA axis, the research provides mechanistic insight into cardiac energy homeostasis and highlights potential targets for heart failure intervention.

• Macrophage-Targeted Mms6 mRNA-LNPs Enhance SCI Recovery in M

  2026-08-03

  Fu et al. developed macrophage-targeted Mms6 mRNA-lipid nanoparticles that significantly improve motor function and tissue repair after spinal cord injury in mice. This approach leverages in vivo mRNA delivery to reprogram endogenous macrophages, circumventing the limitations of cell transplantation and advancing the therapeutic landscape for CNS trauma.

• Oligomycin A: Mitochondrial ATP Synthase Inhibitor in Resear

  2026-08-02

  Oligomycin A is a potent mitochondrial ATP synthase inhibitor used extensively in mitochondrial bioenergetics research. Its precise mechanism enables investigators to dissect metabolic adaptation in cancer and apoptosis pathways, with robust evidence supporting its specificity and reproducibility.

• Minocycline HCl in Neuroinflammation: Protocols & Innovation

  2026-08-01

  Minocycline HCl stands at the intersection of antibacterial and neuroprotective research, enabling robust modeling of inflammation and microglial regulation. This article delivers actionable workflows, troubleshooting, and translational insights for using minocycline hydrochloride in advanced retinal and neurodegenerative assays.

• Potassium Channel Blockade and Renal Hemodynamics in Septic

  2026-07-31

  This study investigates how blocking ATP-sensitive and calcium-activated potassium channels affects renal blood flow in septic rats, revealing an exacerbation of renal hypoperfusion when such blockade is combined with vasoactive drugs. These findings refine our understanding of vascular potassium channel functionality in sepsis and inform research strategies targeting renal perfusion and vascular reactivity.

• Magnetic Nano-antibodies Enable In Vivo CAR-T-Mimicking Ther

  2026-07-31

  This study introduces a magnetic bispecific nano-antibody platform (M-BiNanoAb) for the in vivo generation and magnetic guidance of CAR-T-mimicking cells, directly addressing the longstanding challenges of T cell infiltration and immunosuppression in solid tumor therapy. The findings highlight a non-genetic, magnetically controlled approach with significant preclinical efficacy, offering new directions for solid tumor immunotherapy.

• RP3-340N1.2 Knockdown Destabilizes IL-6 in NSCLC Progression

  2026-07-30

  This study identifies the long non-coding RNA RP3-340N1.2 as a critical stabilizer of IL-6 mRNA in non-small cell lung cancer (NSCLC), promoting tumor proliferation, migration, and tumor-associated macrophage polarization. Knockdown of RP3-340N1.2 accelerates IL-6 mRNA decay by enhancing ZC3H12A-mediated degradation, highlighting a mechanistically defined target for transcriptional regulation and RNA metabolism research.

• Strategic Deployment of ABT-737 in Translational Cancer Rese

  2026-07-30

  This article explores the mechanistic foundation and experimental leverage of ABT-737, a potent BCL-2 protein inhibitor, in translational oncology. It contextualizes current apoptosis induction strategies, benchmarked by ABT-737's preclinical and workflow performance, guiding researchers toward optimized protocol design and forward-looking translational pathways. Drawing on recent advances and competitive insights, the piece delivers nuanced guidance for deploying ABT-737 in models of lymphoma, multiple myeloma, SCLC, and AML, while articulating future directions for apoptosis-targeted therapeutics.

• EZ Cap™ Cre mRNA (m1Ψ): Advanced Gene Editing Workflows

  2026-07-29

  EZ Cap™ Cre mRNA (m1Ψ) empowers precise, immunologically silent gene editing in both in vitro and in vivo settings. Leveraging Cap 1 and m1Ψ modifications, researchers achieve robust recombinase expression, reproducibility, and superior mRNA stability—even in challenging delivery scenarios.

• Translating α2-AR Agonist Mechanisms for Osteosarcoma Recurr

  2026-07-29

  This thought-leadership article explores how selective α2-adrenergic receptor agonists, exemplified by 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine, are redefining strategies for immune rejection modulation in post-surgical osteosarcoma recurrence treatment research. Integrating mechanistic insights from recent literature, protocol parameters, and best practices, we provide actionable guidance for translational researchers seeking to leverage advanced small molecules and delivery systems for more effective tumor immunomodulation.

769 records 9/52 page Previous Next First page 上5页 678910 下5页 Last page